Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Efsitora Alfa vs Degludec in Insulin-Naïve T2D (QWINT-2)
NCT05362058Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2022
- Primary completion
- Apr 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in HbA1c at Week 52. Started Jun 2022; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05362058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362058.